STOCKS TELEGRAPH

Tag: Ocugen

  • Ocugen, Inc. (OCGN) stock gained in the Pre-market; here is why?

    Ocugen, Inc. (OCGN) stock gained in the Pre-market; here is why?

    Ocugen, Inc. (OCGN) gained in the pre-market after announcing the fourth quarter and fiscal 2021 results. OCGN values at $3.17 gained more than 3.92% compared to yesterday’s closing price. The stock closed at $3.06 at the end of the last trading session. The stock volume traded in the last trading session was around 13.32 million shares. The current market cap of the company is around $623.45 million.

    OCGN: Q4 and Fiscal 2021 Key Financials

    • In the fourth quarter of 2021, R&D spending was $7.1 million. Around $1.6 million was spent on R&D in Q4 2020. In the fiscal year 2021, R&D expenses were $35.1.1 million. Around $6.4 million was spent on R&D in fiscal 2020.
    • General and administrative expenses in Q4 2021 were around $7.5 million. In the same quarter of 2020, it was around $2.2 million. General and administrative expense in fiscal 2021 was around $22.2 million. In fiscal 2020 it was around $8 million.
    • When compared to Q4 2020, Q4 2021’s loss per share was $0.07, while the loss per share in Q4 2020 was only $0.02. With a $7.0 million in-process research and development expenditure linked to lowering the carrying value of an asset previously classified as held for sale, OCGN announced a $0.30 net loss per share for the year ended December 31, 2021.

    OCGN Major Business Achievements

    FDA approved Phase 2/3 clinical trial to support a BLA filing in the United States after the FDA withdrew its clinical hold on the IND application for COVAXIN (BBV152).

    Additional neutralization data against Omicron were provided as part of FDA engagement to advance the pediatric EUA for COVAXIN, with more than 36 million vaccinated teens on record.

    The company filed detailed answers to Health Canada’s NOD on COVAXIN.

    For the treatment of hereditary retinal illnesses caused by NR2E3 and RHO disease genotypes, they started OCU400 Phase 1/2 clinical study.

    Conclusion

    Ocugen, Inc. (OCGN) is a pre-revenue company and has recently developed a covid-19 vaccine. The company is also working on researching the treatment of other diseases. The company is looking forward to the approval from NOD Canada for the approval of COVAXIN.

  • Why Is Ocugen (OCGN) Stock Increasing Today?

    The shares of Ocugen Inc. (OCGN) are up 3.58% to $6.67 in early trading this morning. The Ocugen stock was down by -4.17% to $6.44 at the end of the last trading session. There were 13.28 million shares traded in OCGN stock yesterday. That was below the volume of 44.31 million shares in a daily average for the past 50 days.

    OCGN stock has declined 10.06 percent in the last five days; however, it has gained 5.06% over the past month. Over the last three months, the stock price of OCGN has shed -6.67% and is up 251.91% so far this year. In response to a submission to the Canadian health authority, OCGN stock is rising.

    What OCGN has been submitting?

    As a biopharmaceutical company, Ocugen aims to discover, develop, and commercialize gene therapies for blindness diseases and to develop a vaccine against COVID-19. OCGN’s breakthrough platform for gene therapy, which treats multiple retinal diseases with one drug, has the potential to treat multiple diseases with the same drug.

    With OCGN’s novel biologic product candidate, patients with diseases like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy will be able to receive better treatment options. Bharat Biotech’s COVAXIN, a vaccine candidate for COVID-19, is being co-developed by OCGN in the United States and Canada.

    A rolling submission for COVAXIN has been made to Health Canada by Ocugen, announced the company in a press release today. Following the publication of results from Bharat Biotech’s Phase 3 clinical trial, which showed efficacy and safety in nearly 25,800 adults, OCGN intends to make this move.

    The Minister of Health recommended and accepted the rolling submission process relating to the importation, sale and advertising of drugs for use with COVID-19 and transitioned to the New Drug Submission for COVID-19, which will allow companies to submit safety and efficacy information as it becomes available. Often referred to as rolling reviews, this allows Health Canada to begin its review immediately as new information becomes available, allowing the overall review process to move faster.

    How OCGN will proceed?

    In the rolling submission, Ocugen (OCGN) is represented by its affiliate, Vaccigen, Ltd. OCGN must submit evidence that supports the safety, effectiveness, and quality of their product to Health Canada for review. OCGN will work with Health Canada to bring another safe and effective option for the fight against COVID-19 and its Delta variant, and will be supporting Health Canada for their upcoming review of COVAXIN.

  • 7 Biotech Stocks to Buy in 2021

    7 Biotech Stocks to Buy in 2021

    Change is inevitable in every aspect of life because it results from human exploration and applying knowledge to improve life quality. This is why many industries have shown significant growth with time, and the biotech industry is one of them. The biotech industry has extraordinarily impacted healthcare, biological science, economy, and business in recent years. The plethora of biotech stocks continuously put their efforts into developing therapeutics and vaccines that are effective and less toxic, and easily accessible for individuals. With the rise of COVID-19, the Biotech industry has gained more importance. Many biotech stocks have developed and commercialize vaccines in the battle against the deadly pandemic. Now many investors are looking for biotech stocks to get high profits in the future. Here are the 7 biotech stocks to buy in 2021.

    Pfizer (PFE)

    The first and foremost stock to watch in 2021 is Pfizer (PFE), one of the first biotech stocks to market the COVID-19 vaccine. Since then, it has contracted with many governments and supplied millions of doses and looking forward to providing more than this in the future. The U.S government has a plan to vaccinate all of its adult population, and Pfizer is likely to contribute a lot to this cause. While many other biotech stocks only focus on older patients, Pfizer is also developing a COVID-19 vaccine for children, which is another positive sign for future growth. The company has a market cap of more than $220 billion and annual revenue of more than $40 billion. Hence Pfizer stock can be a good bet in 2021. 

    Regeneron Pharmaceuticals (REGN)

    The second stock that could prove fruitful for investors in 2021 is Regeneron Pharmaceuticals(REGN). The company has a market cap of more than $55 billion and is engaged in discovering, developing, and manufacturing various therapeutics to treat medical conditions worldwide. One of the two authorized antibody treatments to treat COVID patients belongs to Regeneron. Its recent first-quarter results show that its quarterly revenue showed 38% growth year over year. Its COVID-19 antibody treatment alone generated $262 million in the first quarter of 2021. Besides this, Eylea, a drug to treat eye diseases, also impacts its increased sales over time. Hereafter, investors need to keep an eye on this stock.

    Novavax (NVAX)

    On Number three, we have Novavax (NVAX). It is another biotech stock engaged in the development of commercialization of vaccines to prevent infectious diseases. Novavax has significantly outperformed in the COVID-19 era and still giving a tough time to its competitors. Its COVID-19 vaccine candidate NVX-CoV2373 could bring massive profits in the future. Novavax is about to finalize the major supply deal with the European Union, which means the supply of 500 million or more doses. So, a lot of money on the line is expected for Novavax stock. 

    Moreover, it has also inked supply deals with many countries in which India is also included, which has more than 1.3 billion population. Novavax generated a breathtaking $447 million in revenue in the first quarter of 2021 compared to $3 million in the same quarter of last year. This significantly increased revenue shows its success over the year. In a nutshell, investors should keep an eye on this stock.

    Bio N Tech SE (BNTX)

    On Number four, we have Bio N Tech (BNTX), which is a biotechnology company engaged in discovering and developing therapeutics to treat various infectious diseases. Bio N Tech is the partner of Pfizer in the battle against COVID-19. BNTX stock expects $26 billion in sales for the COVID-19 vaccine and its partner in 2021 and estimates roughly $3 billion in earnings. Millions of the mutually prepared COVID-19 vaccine doses have been delivered to many countries so far. Both partners are negotiating with many other countries to supply COVID-19 vaccine doses worth $3 billion by 2022, which points to the bright future of BioNTech stock. So it can be a good bet for investors in the future.

    Ocugen (OCGN)

    Ocugen (OCGN), stands at number five on our list. It is a clinical-stage biopharmaceutical company focused on developing therapeutics to cure blindness and other retinal diseases. Ocugen stock is working with Bharat Biotech to develop COVAXIN and the vaccine used to treat COVID patients. The phase-3 study results of COVIXIN showed 100% efficacy against severe coronavirus and 78% efficacy against mild and moderate COVID-19 disease. The Indian government has given emergency use authorization to Bharat Biotech which is a positive sign for Ocugen stock. Ocugen stock is looking forward to developing the COVID-19 vaccine for other markets and can be a good bet for investors in the future.

    Seagen (SGEN) 

    Seagen Inc is an American-based biotech stock focused on developing and commercializing therapeutics to treat cancer patients, and it’s in the Number six position on our list. Seagen has shown significant growth in 2020 as compared to 2019. Its revenue for 2020 totaled $2.2 billion, which shows 140% growth over the year. The revenue for the year 2019 was $916.7 billion. The company has achieved global success with Adcetris, an antibody medicine used to treat lymphoma, and is in an excellent position to invest more in developing newer medications. Therefore, Seagen is one of the biotech stocks to watch in 2021.

    Vertex Pharmaceuticals (VRTX)

    The seventh biotech stock to watch in 2021 is Vertex Pharmaceuticals Incorporated (VRTX), which is mainly focused on developing and commercializing therapeutics to treat cystic fibrosis. Trikafta is the most important drug of Vertex pharmaceutical that treats roughly 90% of patients with cystic fibrosis. Estimates show that 70,000 cystic fibrosis patients are there globally, and Trikafta is the only medication available for this disease. Vertex stock has generated significant revenue through Trikafta and some other products, which will continue to rise in the future. The company has partnered with CRISPR Therapeutics and announced impressive results from a clinical trial of gene therapy for two rare blood diseases. Consequently, its continued success against cystic fibrosis and clinical developments suggests that this stock could outperform in the long run.

    The following three biotech stocks are with the lowest 12-month trailing price-to-earnings ‎ratio (P/E). Dividends and buybacks are two ways a company can return profits to ‎shareholders, so a low P/E ratio shows you are paying less for every dollar of profits ‎generated.

    The Agios Pharmaceuticals (AGIO)‎

    The Agios Pharmaceuticals Inc. platform is a pharmaceutical company dedicated to ‎developing drugs for genetic diseases such as hemolytic anemias and sickle cell disease. In Q1 ‎‎2021, the company reported a net income of $1.9 billion, a far cry from its Q1 2020 loss. ‎Agios’ oncology portfolio was sold to Servier Pharmaceuticals LLC in the first quarter, which ‎had an impact on revenue.

    Sage Therapeutics, Inc.. (SAGE)

    Sage Therapeutics has developed treatment for issues related the central nervous system, including schizophrenia and major depression. The company reported positive results from its SAGE-718 clinical trial, a drug that may be used to treat Huntington disease, in Q1 2021.

    Innoviva Inc. (INVA)

    Innoviva is a healthcare-oriented asset manager that holds portfolios of royalties for many pharmaceuticals.

  • Here is why Ocugen Inc. (OCGN) stock turnaround in the after-hours on Friday?

    Ocugen Inc. (OCGN) shares gained 13.85% in after-hours on Friday, July 2, 2021, and closed at $8.30 per share. Earlier in the morning session on Friday, OCGN’s stock lost 6.90% to close Friday’s session at $7.29. OCGN shares have risen 3195.66% over the last 12 months, and they have moved down 12.69% in the past week. Over the past three months, the stock has gained 10.96%, while over the past six months, it has shed 298.36%.

    Let’s have a look at its recent developments.

    Positive results from phase 3 study of COVAXIN

    On July 02, 2021, Ocugen, Inc, co-development partner, Bharat Biotech, shared positive results of its Phase 3 study of COVAXIN. COVAXIN™ demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%.

    In phase 3 clinical trial, 25,798 participants across 25 sites and between 18-98 years of age in India were enrolled, including 2,750 over the age of 60 and 7,065 with comorbidities.

    Subjects vaccinated with COVAXIN™ in the phase 3 trial, achieved greater protection against emerging B.1.617.2 (delta) and B.1.351 (beta) variants than those who had previous natural infections. The phase 3 results showed an efficacy rate of 65.2% (95% CI; 33.1-83.0).

    New appointment

    On June 21, 2021, Ocugen, Inc appointed Ken Inchausti as Head, Investor Relations & Communications. Mr Inchausti will oversee the company’s investor relations activities, corporate communications and strategic positioning, leading issues management strategy and proactive media and social media relations programming.

    Inducement grants

    On June 18, 2021, the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 157,450 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 26,300 shares of common stock to four new employees.

    Coronavirus Vaccine Manufacturer in the US

    On June 15, 2021, Ocugen, Inc selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN™ to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.

    Ocugen aimed for full U.S. approval of COVAXIN

    On June 10, 2021, Ocugen Inc said that the company is no longer pursue an emergency use authorization for its COVID-19 vaccine candidate and would instead aim to file for a full U.S. approval of the shot.

    The decision is based on FDA asked for more information and data for full approval.

    Conclusion

    The recent phase 3 trial results of COVAXIN showed positive results against deadly variants which was the reason behind its surge in the after-hours on Friday. the OCGN stock can continue its surge on Tuesday, after the long weekend.

     

  • Ocugen, Inc. (OCGN) stock falls in Pre-Market today: Why is it so?

    Ocugen, Inc. (OCGN) stock falls in Pre-Market today: Why is it so?

    Shares of Ocugen, Inc. (OCGN) stock were down in the per market trading session today after recording the gain of 6.69% with an $11.96 per share price. OCGN stock price went down by 3.60% to drop at $11.53 a share at the time of this writing. There is no particular activity by the Ocugen today however OCGN stock on April 28, 2021, announced the closing of a previously announced registered direct offering of common stock. Let’s explore more about OCGN stock.

    What’s happening?

    There is no specific reason behind the declining stock price of the OCGN stock today. No signs of analysts’ downgrade or shrank targeted per share price of the OCGN stock have been in the recent news. The most recent activity by the Ocugen stock is that it announced the closing of the previously announced registered direct offering of its common stock. OCGN stock offered 10 million shares of its common stock to healthcare-focused institutional investors at a purchase price of $10 per share. The gross proceeds resulting from this offering were roughly $100 million without the deduction of placement agent’s fees and other offering-related expenses which Ocugen has to pay.

    Net proceeds resulted from this offering would be used for general corporate purposes and capital expenditures by the OCGN stock. Moreover, part of the proceeds will also be used in the working capital as well as general and administrative expenses by the Ocugen stock.

    COVID-19 Vaccine Development:

    About a week ago, OCGN’s partner Bharat Biotech announced positive data for the second interim analysis of the phase 3 study of Covaxin. According to the data, Covaxin showed 100% efficacy against severe COVID-19 disease, and efficacy of 78% was shown by Covaxin candidate against mild, moderate, and severe COVID-19 disease. After getting encouraging results from the phase 3 study, Ocugen stock is hoping to win the EUA for Covaxin. Currently, Covaxin has been playing a major role in the fight against deadly pandemic in India.

    Conclusion:

    OCGN stock is gloomy so far in the stock market but it showed considerable overall growth in recent times.The positive results of the phase 3 study of Covaxin are the main reason behind this growth but still OCGN stock is lagging in the race of COVID-19 vaccine development as companies like Pfizer, Moderna, and Johnson& Johnson have already contracted the U.S government for the supply of millions of vaccine doses.

  • Ocugen Inc. (OCGN) stock has surged in the premarket trading session. Here’s why

    Ocugen Inc. (OCGN) stock has surged in the premarket trading session. Here’s why

    In the premarket trading session, Ocugen Inc. (OCGN) stock soared by 20.56% to trade at $11.61at the time of writing. OCGN closed Friday’s session at $9.63 with a 3.66% gain. The OCGN stock volume traded 504.64 million shares today. The average volume of trade for the past 3 months has been 69.44 million. In the past year up to date period, OCGN stock surged by 2891.61% while rallying by 66.61% for the past 5 consecutive days. In the last three months, OCGN shares added 341.74%, and further added 2957.14%. In the last six months. Ocugen Inc. is currently valued in the market at $1.75 billion and has 188.09 million outstanding shares.

    Ocugen’s retinal therapy product offering

    Ocugen Inc. is a biopharmaceutical company that is focused on designing, developing, and commercializing of innovative therapies that aim to target the unmet needs of patients with diseases.  The transformative therapies that the company designs are gene therapies that specifically developed for targeting blindness diseases and restoration of sight. Ocugen Inc. uses proprietary modifier gene therapy platform which has become a breakthrough in treating multiple retinal diseases with one drug. Furthermore, OCGN stock has novel therapies for the treatment of age-related macular degeneration (AMD), diabetic retinopathy, and diabetic macular edema.

    Announcing a definitive agreement for a $100 million direct offering

    On 24th April 2021, Ocugen Inc. announced that it entered into an agreement with healthcare-focused institutional investors. This definitive agreement was made for the sale of $100 million registered shares of OCGN’s common stock in a direct offering at a price per share of $10. The deal is expected to take place around 27th April 2021, if everything happens according to customary closing conditions and satisfaction.

    These healthcare-focused institutional investors’ offering were placed through the exclusive placement agent firm known as H.C. Wainwright & Co. The purpose of the offering and the deal is for OCGN stock to use the net proceed for general business activity and corporate purposes.

    Bharat Biotech achieves positive second interim data for its COVAXIN, COVID-19 vaccine study

    On 22nd April 2021, announced that Bharat Biotech (co-development partner) has achieved success in a late-stage study of COVAXIN. COVAXIN is a vaccine in development for COVID-19 and the positive data of the study made the shares of the OCGN stock go up the charts.

    The study of COVAXIN was in its phase III and the second interim analysis demonstrated a positive result of 78% efficacy for COVID-19 in mild, moderate-severe COVID-19 symptoms and variants while the study also claims that in the severe cases of COVID-19, COVAXIN showed 100% efficacy. The study also had a subgroup of participants for the RT-PCR test and found that the efficacy against asymptomatic COVID-19 infection was 70%.

    OCGN stock’s future plans of commercializing

    The company has planned an agreement its co-development partner Bharat Biotech to distribute and commercialize COVAXIN in the U.S market which includes the technology transfer of manufacturing and share in the profits of US market sales- Ocugen will retain 45% of the profit. Furthermore, Bharat Biotech is waiting for the Emergency Use Authorization which will allow it to supply a certain amount of minimum number of COVAXIN doses.

  • Ocugen (OCGN) Stock Price Increased by 270% On A Year To Date Basis. Here’s What Happened

    Ocugen (OCGN) Stock Price Increased by 270% On A Year To Date Basis. Here’s What Happened

    Ocugen (OCGN) stock is a relatively new biotechnology company specializing in diverse and lucrative fields such as gene therapy and Covid 19 vaccines. In February, OCGN made a contractual agreement with Bharat Biotech to produce the Covaxin Covid-19 vaccine, which showed minimal side effects and had an 81% efficacy rate in phase 3 clinical trial in India soaring OCGN Stock price by 270%. Ocugen agreement stipulates that it will commercialize the vaccine in the U.S, targeting a huge demographic and capturing a staggering 45% of the profits from its sale.

    The vaccine produced by OCGN is an inactivated vaccine. Primarily, an inactivated or dead form of the SARS-CoV-2 virus is inserted into the human bloodstream. Afterwards antibody production is started by the immune system and the body ‘Learns’ the defense mechanism. Hence if an infection occur, the immune system can respond swiftly and efficiently.

    Now What

    Financially, the company consists of over $24 million in capital and has approximately $2.1 million in debt. In 2020, its net losses were $21.8 million, however new OCGN stock can be issued to generate capital and new income from vaccines could further help Ocugen to diversify its pipeline.

    Furthermore, Pfizer, Moderna, and AstraZeneca have already started mass production of their vaccines, hence OCGN can have a hard time grabbing a significant share in the saturated market. However, Bharat Biotech claims that Covaxin demonstrates “significant immunogenicity against the rapidly emerging variants.” giving OCGN product line distinctive competency over other vaccines which can produce a potentially huge financial surplus.

    Conclusion

    OCGN has invested in a very lucrative market of vaccines especially amongst the time of a pandemic. A strategic relationship with Bharat Biotech combined with an 81% efficacy rate of the vaccine has peaked investor interest with speculations of high capital gains in the near future.

  • Why Ocugen, Inc. (OCGN) looks set to accumulate more gains?

    Why Ocugen, Inc. (OCGN) looks set to accumulate more gains?

    Ocugen, Inc. (OCGN) was up another 60% in aftermarket trading on Friday after the company announced it had signed definitive agreements for the sale of an aggregate of 3,000,000 shares of common stock to healthcare-focused institutional investors. The shares were offered in a registered direct offering at $7.65 per share. The offering will close on or about February 10, 2021, pending the satisfaction of the usual closing conditions. The exclusive placement agent for the issuer is H.C. Wainwright & Co.

    Before deducting placement agent’s fees and other offering expenses Ocugen will receive approximately $23 million in gross proceeds. Ocugen intends to use its net proceeds from the offering to fund working capital, capital expenditures, and its general and administrative expenses.

    OCGN is already up 200% over week

    The stock skyrocketed around 200% last week after the biopharmaceutical firm struck a deal to develop a promising coronavirus vaccine candidate to be used in the United States. The deal prompted Roth Capital analyst ZegbehJallah to raise the firm’s price target on Ocugen from $1 to $8. Based on the research note, Jallah explains that the terms of the deal are favorable, including no upfront payment so that the company can start off with a positive cash flow.

    What Was Behind The Happy Weekend

    On Friday, Ocugen shares rose 61.5%, following another upbeat analyst note.

    SwayampakulaRamakanth of H.C. Wainwright increased his rating for Ocugen’s stock to buy from neutral on Thursday and forecasted a $4.50 target price for the stock. Ramakanth supported the recent deal between Ocugen and India’s Bharat Biotech, which could potentially deliver Covaxin, a candidate vaccine for COVID-19, to the U.S. market.

    Ramakanth suggests Covaxin could induce a greater level of immunity and better protection against new strains of coronavirus than the COVID-19 vaccine that has been given an emergency use authorization in the U.S. He also emphasized the logistical advantages of covaxin’s less onerous storage requirements, thereby enhancing its competitive edge.

  • Don’t Miss these 15 Biotechnology Value Stocks

    Biotech and Major Pharmaceuticals are back in the news with the Covid-19 Pandemic. Life science investors basically endorse developments that might decide the human race’s future, but what would invest in ‘cures’ mean from a cash flow point of view?
    On Thursday, a panel of independent health professionals voted 17-4 in support of the Food and Drug Administration(FDA), providing emergency permission to the applicant for the COVID-19 vaccine from BioNTech and Pfizer Inc.
    In other news Gilead Sciences Inc (GILD) revealed that it would buy MYR GmbH in cash for roughly EUR 1.15 billion ($1.39 billion), granting it access to the German biotech company’s therapy for extreme viral hepatitis.
    In yesterday’s trading session, the following stocks were the major key players.

    Immutep Limited (NASDAQ:IMMP) shares were trading up 163.43% at $5.69 at the time of writing on Thursday after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.

    Immutep Limited (NASDAQ:IMMP) share price went from a low point around $0.53 to briefly over $3.10 in past 52 weeks, though shares have since pulled back to $5.69. IMMP market cap has remained high, hitting $280.46M at the time of writing.

    If we look at the recent analyst rating IMMP, B. Riley FBR initiated coverage on IMMP shares with a Buy rating.

    TG Therapeutics Inc. (TGTX) stock soar by 40.85% to $41.72 after reportingpositive topline results from the ULTIMATE I & II Phase 3 studies evaluating Ublituximab Monotherapy for the treatment of patients with multiple sclerosis. The most recent rating by JP Morgan, on September 01, 2020, is at an Overweight.

    Heat Biologics Inc. (HTBX) last closed at $0.93, in a 52-week range of $0.19 to $4.30.

    Sangamo Therapeutics Inc. (NASDAQ:SGMO) Shares headed rising, higher as much as 52.98%. Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO), on December 7, 2020 declared updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. The most recent rating by BofA Securities, on September 08, 2020, is at a Buy.

    Entera Bio Ltd. (NASDAQ:ENTX) rose 8.18% after gaining more than $0.09 on Thursday following the firm revealed FDA approval of IND application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.

    Aytu BioScience Inc. (AYTU) last closed at $8.13, in a 52-week range of $3.35 to $29.90 after announcing definitive merger agreement with Neos Therapeutics, creating a combined $100M revenuespecialty pharmaceutical company.

    Amarin Corporation plc (AMRN) stock soar by 8.04% to $4.97. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Editas Medicine Inc. (NASDAQ:EDIT) Shares headed rising, higher as much as 32.15% following an announcement from the company that it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of EDIT-301. The most recent rating by Wells Fargo, on December 10, 2020, is at an Overweight.

    Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) rose 9.04% after gaining more than $0.15 on Thursday.

    Akebia Therapeutics Inc. (AKBA) last closed at $2.95, in a 52-week range of $2.09 to $13.71. The firm recently revealed the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 5.37% to $7.65. The company recently announced transactions with Royalty Pharma (RPRX) and Athyrium Capital Management, LP, totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    Acasti Pharma Inc. (NASDAQ:ACST) Shares headed rising, higher as much as 1.70%. The company on November 16, 2020 released its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. The most recent rating by Oppenheimer, on September 01, 2020, is at a Perform.

    Ocugen Inc. (NASDAQ:OCGN) fall -1.79% after losing more than -$0.01 on Thursday after reporting that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020.

    Inovio Pharmaceuticals Inc. (INO) last closed at $11.36, in a 52-week range of $2.42 to $33.79. The firm recently revealedthe successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. Analysts have a consensus price target of $13.71.

    Cellectar Biosciences Inc. (CLRB) stock soar by 3.47% to $2.09. The most recent rating by Oppenheimer, on July 01, 2020, is at an Outperform.

  • 49 Stocks Making Sharp Moves in Pre Market Session

    49 Stocks Making Sharp Moves in Pre Market Session

    BlackBerry Limited (BB) stock soared 21.29% to $8.49 in the pre-market trading following the announcement of its multi-year, global agreement with Amazon Web Services, Inc. (AWS). The most recent rating by TD Securities, on April 01, 2020, is a Hold.
    Gores Metropoulos Inc. (GMHI), a Shell Companies company, dropped about -3.71% at $16.37 in pre-market trading Wednesday.
    Carnival Corporation & Plc (NYSE: CCL) shares are trading up 2.48% at $20.65 at the time of writing. The firm recently reported Peter C. Anderson as a Section 16 Named Executive Officer. Company’s 52-week ranged between $7.80 to $51.94. Analysts have a consensus price target of $31.
    Guardion Health Sciences Inc. (GHSI) is up more than 2.11% at $0.3 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 11.71% to $0.29 in the last trading session.
    Advaxis Inc. (ADXS) grew over 0.85% at $0.32 in pre-market trading today. The healthcare company recently announced closing of $9.2 million public offering.
    Before the trading started on December 02, 2020, RiceBran Technologies (RIBT) is down -5.56% to reach $0.68. It has been trading in a 52-week range of $0.37 to $2.43.
    Sundial Growers Inc. (SNDL) stock moved up 5.75 percent to $0.69 in the pre-market trading and the company recently announced elimination of senior secured second lien convertible notes.
    Kaixin Auto Holdings (KXIN) is up more than 4.55% at $7.35 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 8.32% to $7.03 in the last trading session.
    Moleculin Biotech Inc. (MBRX) lost over -7.83% at $0.9125 in pre-market trading Wednesday December 02, 2020 after declaring that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066.
    Jaguar Health Inc. (JAGX) stock plunged -5.83% to $0.4313 in the pre-market trading. The most recent rating by Rodman & Renshaw, on July 11, 2017, is a Buy.
    Auris Medical Holding Ltd. (EARS) stock plunged -17.97% to $4.29 in the pre-market trading after reporting positive efficacy data from testing AM-301 in vitro. The most recent rating by Euro Pacific Capital, on October 08, 2018, is a Buy.
    Before the trading started on December 02, 2020, Sunworks Inc. (SUNW) is up 9.88% to reach $4.67. It has been trading in a 52-week range of $0.29 to $8.50.
    China Automotive Systems Inc. (NASDAQ: CAAS) shares are trading down -4.95% at $8.25 at the time of writing after the firm declared that its shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. Company’s 52-week ranged between $1.42 to $10.50.
    Tilray Inc. (NASDAQ: TLRY) shares are trading up 1.61% at $8.2 at the time of writing. Company’s 52-week ranged between $2.43 to $22.95. Analysts have a consensus price target of $4.77.
    Ocugen Inc. (OCGN) lost over -8.87% at $0.3101 in pre-market trading Wednesday December 02, 2020. The company recently reported that leading independent proxy firms ISS and Glass Lewis recommended Ocugen stockholders vote “FOR” reverse stock split and authorized shares amendment proposals.
    AMC Entertainment Holdings Inc. (AMC) is up more than 2.41% at $4.25 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -2.81% to $4.15 in the last trading session.
    Before the trading started on December 02, 2020, JetBlue Airways Corporation (JBLU) is down -4.67% to reach $14.7 following the declaration of its pricing of common stock offering. It has been trading in a 52-week range of $6.61 to $21.65.
    Before the trading started on December 02, 2020, Uxin Limited (UXIN) is down -3.65% to reach $1.32. It has been trading in a 52-week range of $0.72 to $3.10.
    Li Auto Inc. (NASDAQ: LI) shares are trading up 1.78% at $35.48 at the time of writing after announcing that the Company delivered 4,646 Li ONEs in November 2020. Company’s 52-week ranged between $14.31 to $47.70. Analysts have a consensus price target of $45.60.
    Aurora Cannabis Inc. (ACB) stock soared 3.59% to $10.1 in the pre-market trading. The most recent rating by Jefferies, on November 16, 2020, is an Underperform.
    Tantech Holdings Ltd (TANH), a Household & Personal Products company, dropped about -3.24% at $1.79 in pre-market trading Wednesday after reporting the launch by its subsidiary, Shangchi Automobile Co., Ltd., of its newest highly innovative driverless and autonomous street sweeper.
    Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) shares are trading down -5.52% at $1.37 at the time of writing. Company’s 52-week ranged between $0.91 to $9.78. Analysts have a consensus price target of $3.
    iBio Inc. (IBIO) is up more than 19.31% at $1.73 in pre-market hours Wednesday December 02, 2020 after revealing that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. The stock had dropped over -2.68% to $1.45 in the last trading session.
    Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) shares are trading up 2.09% at $23.42 at the time of writing. Company’s 52-week ranged between $7.03 to $59.78. Analysts have a consensus price target of $26.
    Moderna Inc. (MRNA) stock soared 6.09% to $149.6 in the pre-market trading. The biotechnology firm reported recently, that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    Switchback Energy Acquisition Corporation (SBE) is down more than -4.16% at $28.13 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -12.67% to $29.35 in the last trading session.
    Novavax Inc. (NVAX) grew over 4.84% at $129.44 in pre-market trading today after declaring COVID-19 vaccine clinical development progress.
    Before the trading started on December 02, 2020, Eastman Kodak Company (KODK) is up 3.88% to reach $7.5. It has been trading in a 52-week range of $1.50 to $60.00.
    ReneSola Ltd (SOL), a Solar company, dropped about -11.66% at $6.97 in pre-market trading Wednesday after releasing its third quarter 2020 financial results.
    Acasti Pharma Inc. (ACST) stock plunged -9.56% to $0.3301 in the pre-market trading. The most recent rating by Oppenheimer, on September 01, 2020, is a Perform.
    Pfizer Inc. (PFE) stock moved up 3.73 percent to $40.88 in the pre-market trading after the firm and BioNTech SE reporting that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19.
    Gevo Inc. (NASDAQ: GEVO) shares are trading down -3.17% at $1.83 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.
    Fisker Inc. (FSR) is down more than -3.41% at $17.55 in pre-market hours Wednesday December 02, 2020. The company recently reported that that Henrik Fisker, chairman and chief executive officer of Fisker, will participate in the Credit Suisse Eighth Annual Virtual Industrials Conference. The stock had dropped over -6.24% to $18.17 in the last trading session.
    Nxt-ID Inc. (NXTD) grew over 43.17% at $0.587 in pre-market trading today.
    Before the trading started on December 02, 2020, Bloom Energy Corporation (BE) is down -6.58% to reach $23.0 and the company will host virtual analyst day on December 16, 2020. It has been trading in a 52-week range of $3.00 to $28.24.
    Ocean Power Technologies Inc. (OPTT), a Electrical Equipment & Parts company, dropped about -3.54% at $2.45 in pre-market trading Wednesday.
    Nikola Corporation (NKLA) stock soared 4.38% to $18.13 in the pre-market trading after signing MOU with General Motors. The most recent rating by Loop Capital, on November 20, 2020, is a Buy.
    Vaxart Inc. (VXRT) gained over 3.92% at $7.95 in pre-market trading Wednesday December 02, 2020.
    salesforce.com inc. (CRM) lost over -4.16% at $231.3 in pre-market trading Wednesday December 02, 2020 after introducing service cloud workforce engagement to help contact centers thrive in an all-digital, work-from-anywhere world.
    InVivo Therapeutics Holdings Corp. (NVIV), a Biotechnology company, rose about 2.42% at $0.635 in pre-market trading Wednesday.
    FuelCell Energy Inc. (FCEL) stock plunged -20.11% to $7.23 in the pre-market trading following the publication pricing of its underwritten public offering of 34,518,539 shares of its common stock, at a public offering price of $6.50 per share. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.
    Pershing Square Tontine Holdings Ltd. (PSTH), a Shell Companies company, rose about 2.34% at $26.25 in pre-market trading Wednesday.
    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading up 4.37% at $29.59 at the time of writing after reporting its new flight window since it paused the spaceflight preparations in response to state guidelines from the New Mexico Department of Health to reduce the spread of COVID-19. Company’s 52-week ranged between $7.14 to $42.49. Analysts have a consensus price target of $19.
    Second Sight Medical Products Inc. (EYES) stock moved down -8.0 percent to $1.38 in the pre-market trading.
    BioNTech SE (BNTX) grew over 7.36% at $122.4 in pre-market trading today after declaring that it will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2.
    Sogou Inc. (SOGO), a Internet Content & Information company, rose about 3.09% at $8.68 in pre-market trading Wednesday.
    Tellurian Inc. (TELL) is down more than -4.29% at $1.56 in pre-market hours Wednesday December 02, 2020 and the firm recently declared the appointment veteran CEO and adds industry experts to board of directors. The stock had jumped over 9.40% to $1.63 in the last trading session.
    Arlo Technologies Inc. (ARLO) lost over -3.48% at $6.66 in pre-market trading Wednesday December 02, 2020.
    Before the trading started on December 02, 2020, ZoomInfo Technologies Inc. (ZI) is down -3.57% to reach $46.22 as the firm announced pricing of secondary offering of shares of class a common stock. It has been trading in a 52-week range of $30.83 to $64.40.